Table 3. Univariable and multivariable analysis of overall survival.
| Variable | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Gender (male vs. female) | 1.671 (0.75–3.75) | 0.213 | – | – | |
| Age (≥60 vs. <60 years) | 1.33 (0.69–2.57) | 0.395 | – | – | |
| Pathological type (SCC vs. non-SCC) | 1.35 (0.68–2.67) | 0.386 | – | – | |
| Smoking (yes vs. no) | 0.56 (0.27–1.17) | 0.12 | – | – | |
| ECOG (0 vs. 1) | 1.22 (0.60–2.49) | 0.575 | – | – | |
| Line of immunotherapy (≤2nd vs. >2nd) | 1.51 (0.81–2.82) | 0.196 | – | – | |
| Pretreatment metastases (≥2 vs. <2) | 0.82 (0.39–1.70) | 0.589 | – | – | |
| LIPI score (good vs. poor) | 0.48 (0.26–0.88) | 0.018 | 0.49 (0.28–0.85) | 0.012 | |
| mGPS (good vs. poor) | 0.63 (0.28–1.40) | 0.253 | – | – | |
| TMB (high vs. low) | 0.83 (0.41–1.69) | 0.616 | – | – | |
SCC, squamous cell carcinoma; non-SCC, non-squamous cell carcinoma; ECOG, eastern cooperative oncology group performance status; LIPI, lung immune prognostic index; mGPS, modified Glasgow Prognostic Score; TMB, tumor mutational burden; HR, hazard ratio; CI, confidence interval.